🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
4.780
-0.090 (-1.85%)
At close: Nov 18, 2026, 4:00 PM EST
4.827
+0.047 (0.99%)
After-hours: Nov 18, 2026, 6:46 PM EST

Company Description

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.

It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.

The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease.

It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.

The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.

Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals logo
CountryUnited States
Founded1998
IPO DateFeb 3, 2010
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees100
CEOThomas McCourt

Contact Details

Address:
100 Summer Street, Suite 2300
Boston, Massachusetts 02110
United States
Phone617 621 7722
Websiteironwoodpharma.com

Stock Details

Ticker SymbolIRWD
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001446847
CUSIP Number46333X108
ISIN NumberUS46333X1081
Employer ID04-3404176
SIC Code2834

Key Executives

NamePosition
Thomas A. McCourtChief Executive Officer and Director
Tammi GaskinsSenior Vice President and Chief Commercial Officer
Ronald SilverSenior Vice President, Interim Chief Financial Officer, Corporate Controller and Chief Accounting Officer
Dr. Rosario Lobrutto M.B.A., M.S., Ph.D.Vice President and Global Head of Technical Operations
Chris StammVice President of Investor Relations and Communications
John MinardoSenior Vice President, Chief Legal Officer and Secretary
Jeff RubertiChief Strategy Officer
Dr. Jeffrey Silber M.D.Chief Medical Officer, Head of Research and Drug Development

Latest SEC Filings

DateTypeTitle
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 13, 2026144Filing
Nov 10, 2026SCHEDULE 13GFiling
Nov 5, 2026S-8Securities to be offered to employees in employee benefit plans
Nov 5, 202610-QQuarterly Report
Nov 5, 20268-KCurrent Report
Oct 28, 2026SCHEDULE 13G/AFiling
Oct 16, 20268-KCurrent Report
Sep 23, 2026144Filing
Aug 14, 2026SCHEDULE 13G/AFiling
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides